Table 5 Literature reviews of metformin and breast cancer
Study | Year | Study population of breast cancer | Number (met/non-met/non-DM) | DFS | CSS | OS | Follow up (months or years) | HR (met versus non-met)1; 95 % CI | Special subgroup | Duration of metformin treatment | Tumor characteristics |
|---|---|---|---|---|---|---|---|---|---|---|---|
He et al. [15] | 2012 | Stage II, HER2+ only | 88/66/1829 | N | Y | Y | 47.6 | OS (HR 0.52; 0.28 to 0.97) | Â | NA | Done |
CSS (HR 0.47; 0.24 to 0.90) | |||||||||||
Bayraktar et al. [17] | 2012 | Triple-negative only | 63/67/1318 | Y | Y | Y | 62 | OS (HR 1.22; 0.66 to 2.28) | Â | NA | Done |
RFS (HR 1.37; 0.78 to 2.40) | |||||||||||
DMFS (HR 1.63; 0.87 to 3.06) | |||||||||||
Peeters et al. [12] | 2013 | All | 508/550/NA | N | Y | Y | Â | OS (HR 0.74; 0.58 to 0.96) | Increased risk in the first 12 months after discontinuation | Done | NA |
CSS (HR 0.88; 0.59 to 1.29) | |||||||||||
Lega et al. [14] | 2013 | All | 1094/1267/NA | N | Y | Y | 4.5 (years) | OS (HR 0.97; 0.92 to 1.02) | Â | Done | NA |
CSS (HR 0.91; 0.81 to 1.03) | |||||||||||
Hou et al. [18] | 2013 | All | 419/594/4612 | N | N | Y | 68 | OS2 (HR 0.762; 0.6 to 0.986) | Â | NA | Done |
OS3 (HR 1.708; 1.461 to 1.997) | |||||||||||
Xiao et al. [19] | 2014 | Luminal | 275/405/5105 | N | Y | Y | 70 | OS (HR 3.579; 1.506 to 8.506) luminal A | Â | NA | Done |
OS (HR 3.232;1.839 to 5.678) luminal B (high Ki67) | |||||||||||
OS (HR 2.034;1.019 to 4.059) Luminal B (HER2+) | |||||||||||
Kim et al. (present study) | Â | All | 202/184/6581 | Y | Y | Y | 100 | OS (HR 1.87;1.25 to 2.81) | 1.Hormone receptor+/HER2 + | NA | Done |
CSS (HR1.85;1.17 to 2.92) | 2.Chemotherapy and endocrine therapy | ||||||||||
DFS (HR 1.59, 1.06 to 2.39) |